Anti-hCD19-CAR(3G) Stable Cell Line - THP-1

CAR T cell therapy for CD19 B cell malignancies may be limited by acute toxicities and immunoglobulin replacement due to persistent CAR T cell-induced B cell aplasia. Researchers developed a mouse model to investigate the toxicity mechanisms of Anti-hCD19-CAR and test safer CAR T cells. By transferring human CD19-specific mouse CAR T cells into mice with hemizygous hCD19 transgene expression, resembling human B cells, they observed undetectable tumor levels and B cell aplasia in recipients. Toxicities, including cytokine release syndrome, mirrored patient complications. IL-6, IFN-γ, and inflammatory pathway transcripts were enriched in affected tissues. Neutralization of IL-6 attenuated toxicity, while decreased microglial cells suggested neurotoxicity. This model will aid in evaluating strategies to enhance the safety of hCD19-specific CAR T cells.

Figure 1. Researchers investigated the impact of Anti-hCD19-CAR on CART-19 T cells activation. They cocultured CART-19 T cells with hCD19TG+/− B cells and observed increased CD marker expression and cytokine production. Additionally, CART-19 T cells effectively eliminated hCD19TG+/− B cells in vitro and in vivo, highlighting their potent anti-tumor activity.(Pennell CA, et al., 2018)

Explore the potential of Creative Biogene's Anti-hCD19-CAR(3G) Stable Cell Line - THP-1 for cancer research. Assess CAR-T cell activation, cytotoxicity, and cytokine production against CD19-positive malignancies. Accelerate your preclinical studies and advance cancer immunotherapy.